CSIMarket Company Name, Ticker, Industry, else..
 
Taysha Gene Therapies Inc   (NASDAQ: TSHA)
 

Taysha Gene Therapies Inc's Suppliers Performance

TSHA's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
TSHA Costs vs Sales of Suppliers Growth

• More on TSHA Suppliers






Taysha Gene Therapies Inc's Comment on Supply Chain


The company depends on a limited number of suppliers for specific raw materials, cells, and reagents, including AAV9 raw materials used in all current and planned product candidates. It maintains supplier relationships for manufacturing plasmids and viruses, which are components of its product candidates. Production is conducted through contract manufacturers (CMOs) and is subject to regulatory requirements such as current Good Manufacturing Practice (cGMP) standards in the European Union. The company faces risks related to potential shortages, delays, or inability to obtain raw materials, as well as challenges in regulatory compliance and manufacturing capacity. Additionally, intellectual property licensing may be necessary for manufacturing processes not owned by suppliers or available in the public domain.

Taysha Gene Therapies Inc's Comment on Supply Chain


The company depends on a limited number of suppliers for specific raw materials, cells, and reagents, including AAV9 raw materials used in all current and planned product candidates. It maintains supplier relationships for manufacturing plasmids and viruses, which are components of its product candidates. Production is conducted through contract manufacturers (CMOs) and is subject to regulatory requirements such as current Good Manufacturing Practice (cGMP) standards in the European Union. The company faces risks related to potential shortages, delays, or inability to obtain raw materials, as well as challenges in regulatory compliance and manufacturing capacity. Additionally, intellectual property licensing may be necessary for manufacturing processes not owned by suppliers or available in the public domain.







TSHA's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Taysha Gene Therapies Inc 1,904.27 8.10 -149.63 99
SUBTOTAL 0.00 0.00 0.00 -


Sources: Taysha Gene Therapies Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Taysha Gene Therapies Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.